A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Inclusion Criteria:

1. At least 18 years of age.

2. Histologically or cytologically confirmed stage IV non-squamous Non-Small Cell LungCancer (NSCLC).

3. Participant has no prior systemic treatment for advanced disease.

4. Measurable disease according to RECIST v1.1.

5. Tumor tissue from the resected site of disease must be available for biomarkeranalyses in order to be randomized.

6. Eastern Cooperative Oncology Group performance status score 0 or 1.

7. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-rosoncogene 1, receptor tyrosine kinase of the insulin receptor family (ROS-1) negative

8. Have a life expectancy of at least 3 months.

Exclusion Criteria:

1. Small cell lung cancer (SCLC) or mixed SCLC/NSCLC histology or squamous cellcarcinoma.

2. Participant has active central nervous system metastases not previously treated.

3. Participant has active or known immune-mediated disorders.

4. Participant has received prior systemic cytotoxic chemotherapy, immunotherapy (including PD-1/PD-L1), anti-neoplastic biological therapy, or targeted therapy foradvanced/metastatic disease.

5. Known hypersensitivity to monoclonal antibodies or to any of the excipients of thestudy drug, or to any component of cisplatin, carboplatin, or pemetrexed.